Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal Phase 3 Study of VLA1553 (Ixchiq) in Adults
NCT04546724Phase 3Completed
- Sponsor
- Valneva
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of chikungunya vaccine (live) in chikungunya virus infection, sponsored by Valneva. Started Sep 2020; status: completed.
02
Drugs
chikungunya vaccine (live)
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT04546724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546724.